Lung Cancer Screening at Smilow Cancer Hospital and Yale Cancer Center

Background: To describe the characteristics and outcomes of patients with a clinical diagnosis of COVID-19 and false-negative SARS-CoV-2 reverse transcription-PCR (RT-PCR), and develop and internally validate a diagnostic risk score to predict risk of COVID-19 (including RT-PCR-negative COVID-19) among medical treatment. Case presentation: Herein, we report a 42-year-old male patient from myagdi district Nepal presenting with high grade fever, dry cough, headache and dizziness on the August 10, 2021 during second phase of COVID-19 pandemic. There is no history of hypertension and diabetes. He went for RT-PCR test at local COVID-19 screening center and reported as negative for RT-PCR test. After that he referred to Lumbini Zonal hospital for further evaluation. RT-PCT swab test was performed again and reported negative. On the chest X-Ray, there was opacity on both lungs and the patient was referred to cancer hospital for lung cancer screening. The patient underwent for HRCT chest and biochemical laboratory tests for further evaluation. The chest High Resolution Computed Tomography (HRCT) indicated ground grass opacity (GGO) with crazy paving a typical COVID-19 interstitial pneumonia. In the biochemical laboratory test, there were elevation in Leukocyte (Total WBC count), Neutrophil, Glucose, Bilirubin Direct, Bilirubin Total, SGOT/AST, SGPT/ALT and Lactate Dehydrogenase (LDH). There was low count found in Lymphocyte, Eosinophil and Monocyte. These laboratory parameters findings are typical sign of COVID-19 patients. Then patient was isolated and treatment of given according to COVID-19 treatment guidelines. On September 12, 2021, all diagnostic tests showed that patient recovered from COVID-19. Conclusion: It is safe to suggest that a symptomatic patient with typical chest HRCT and lab findings for COVID-19 should be quarantined or isolated even with 2 negative RT-PCR tests.

Download Full-text

Lung-RADS usado no rastreamento do câncer de pulmão: a doença granulomatosa faz diferença?

Revista de Ensino, Ciência e Inovação em Saúde ◽

10.51909/recis.v2i2.61 ◽

2021 ◽

Vol 2 (2) ◽

pp. 39-43

Author(s):

Julia Noschang ◽

Karen Chaves ◽

Fabio Haddad ◽

Paula Barbosa ◽

Almir Bitencourt ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Screening ◽

Lung Cancer Screening ◽

Data System ◽

Lung Imaging ◽

Cancer Center ◽

Cancer Screening Trial ◽

Screening Trial

Objetivo: o objetivo é analisar os resultados do rastreamento do câncer de pulmão por tomografia computadorizada de baixa dose (LDCT) por meio do Sistema de Relatórios e Dados de Triagem de TC de Pulmão (Lung-RADS) em um centro de câncer brasileiro. Materiais e métodos: revisamos retrospectivamente os prontuários de pacientes submetidos ao programa de rastreamento de câncer de pulmão de LDCT basal no A.C. Camargo Cancer Center. Os critérios de inclusão e exclusão foram iguais aos do National Lung Cancer Screening Trial (NLST). Os critérios para achados de imagem foram aqueles classificados de acordo com as categorias de avaliação do Lung Imaging Reporting and Data System (Lung-RADS). Resultados: Dos 287 indivíduos avaliados neste estudo, 72,1% apresentaram TC de triagem negativa (categorias 1 ou 2 do Lung-RADS), o restante teve TC de triagem positiva, considerando 5,6% na categoria 4A de Lung-RADS, 2,1% na categoria 4B e 1,0% na categoria 4X. Os principais achados foram avaliados em 218 (75,9%) indivíduos, com nódulos sólidos (64,8%), parcialmente sólidos (2,7%) e não sólidos (8,3%). A maioria dos pacientes (59,1%) apresentaram nódulos sólidos menores que 6 mm. Os resultados histológicos confirmaram câncer de pulmão em 2 casos (prevalência de 0,7% de todos os pacientes triados). Conclusões: A prevalência de câncer de pulmão em nossa amostra foi compatível com a literatura. No entanto, tivemos uma prevalência maior das categorias 3 e 4A do Lung-RADS do que o esperado. Isso pode estar associado à maior incidência de doenças granulomatosas, principalmente tuberculose, na população brasileira.

Download Full-text

Patient with false negative RT-PCR for COVID-19 referred to cancer hospital for lung cancer screening: A case report

Journal of Biomedical Sciences ◽

10.3126/jbs.v8i2.41961 ◽

2021 ◽

Vol 8 (2) ◽

pp. 50-54

Author(s):

Ajay Kumar Yadav ◽

Suman Gnawali ◽

Sandip Mandal ◽

Gyan Bahadur Shrestha ◽

Gangbiao Yuan

Keyword(s):

Lung Cancer ◽

Cancer Screening ◽

Treatment Guidelines ◽

False Negative ◽

Lung Cancer Screening ◽

Symptomatic Patient ◽

Rt Pcr ◽

Biochemical Tests ◽

High Grade Fever ◽

Cancer Hospital

Background: Even though RT-PCR tests are generally considered the gold standard for diagnosing SARS-CoV-2, they are not without flaws, and the likelihood of detecting an infection varies depending on when the test is performed. There is chance of false negative due to different pitfalls. So there is essential of correlation of radiological characteristics, abnormalities in biochemical tests and symptoms of suspected patient during COVID-19 epidemic. Case presentation: Herein, we report a 42-year-old male patient with high-grade fever, dry cough, headache and dizziness. He went for the RT-PCR test two times and reported negative. On the chest X-Ray, there was opacity on both lungs and referred to cancer-hospital for lung-cancer screening. The patient underwent chest-HRCT and laboratory tests for further evaluation and was identified as typical COVID-19 findings. Then the patient was isolated and treatment of given according to COVID-19 treatment guidelines Conclusion: It is concluded that a clinically symptomatic patient with typical chest HRCT and abnormal lab findings for COVID-19 should be considered as a COVID-19 patient and isolated even with two negative RT-PCR tests.

Download Full-text

Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites

Journal of Clinical Medicine ◽

10.3390/jcm9061820 ◽

2020 ◽

Vol 9 (6) ◽

pp. 1820

Author(s):

Cary A. Presant ◽

Ravi Salgia ◽

Prakash Kulkarni ◽

Brian L. Tiep ◽

Shamel Sanani ◽

...

Keyword(s):

Lung Cancer ◽

Smoking Cessation ◽

Cancer Screening ◽

Tobacco Control ◽

Lung Cancer Screening ◽

Comprehensive Cancer Center ◽

Cancer Center ◽

Patient Centered ◽

Clinician Training ◽

Treatment Research

Lung cancer is one of the deadliest and yet largely preventable neoplasms. Smoking cessation and lung cancer screening are effective yet underutilized lung cancer interventions. City of Hope Medical Center, a National Cancer Institute (NCI)- designated comprehensive cancer center, has 27 community cancer centers and has prioritized tobacco control and lung cancer screening throughout its network. Despite challenges, we are implementing and monitoring the City of Hope Tobacco Control Initiative including (1) a Planning and Implementation Committee; (2) integration of IT, e.g., medical records and clinician notification/prompts to facilitate screening, cessation referral, and digital health, e.g., telehealth and social media; (3) clinician training and endorsing national guidelines; (4) providing clinical champions at all sites for site leadership; (5) Coverage and Payment reform and aids to facilitate patient access and reduce cost barriers; (6) increasing tobacco exposure screening for all patients; (7) smoking cessation intervention and evaluation—patient-centered recommendations for smoking cessation for all current and recent quitters along with including QuitLine referral for current smokers and smoking care-givers; and (8) establishing a Tobacco Registry for advancing science and discoveries including team science for basic, translation and clinical studies. These strategies are intended to inform screening, prevention and treatment research and patient-centered care.

Download Full-text